A Multi-center Retrospective Analysis of Clinical Character Outcome and Prognosis of Lymphoepithelioma-like Carcinoma

  • End date
    Dec 31, 2021
  • participants needed
  • sponsor
    Sun Yat-sen University
Updated on 26 January 2021


The investigators retrospective collect the clinical data of patients diagnosed with lymphoepithelioma-like carcinoma, including primary site, gender, age, smoking history, tumor stage, time of initial treatment, EBV-DNA copy number, first-line treatment and survival status.


Lymphoepithelioma-like carcinoma (LELC) is a rare EBV-related tumor. Its histology is similar to that of nasopharyngeal carcinoma. In 2004, the WHO classified LELC into one subtype of large cell carcinoma, and the 2015 WHO classified it as other and unclassified cancers. LELC can originate in many organs, including parotid glands, throat, lungs, digestive tract, genitourinary system, etc. Driver gene mutations are rarely seen, and most of them are PD-L1 positive. In terms of treatment, there is no standard first-line treatment for lymphoepithelioma-like cancer. Patients with early-stage lymphoepithelioma-like cancer can receive surgery or radiotherapy, while palliative radiotherapy or chemotherapy is the main treatment for patients in advanced stage. The survival time is about 107 months, the 5-year OS is 59.5%, which is better than the prognosis of lung squamous cell carcinoma in the same period. A retrospective study of Sun yat-sen University Cancer Hospital included 127 patients with advanced lung LELC who received first-line chemotherapy between 2007 and 2018. Gemcitabine and platinum based chemotherapy and paclitaxel and platinum based regimens are significantly better than pemetrexed and platinum, but most of the current studies on lymphoepithelioma-like cancer focus on LELC that originates in the lung. But for other sites, such as parotid glands, liver, digestive tract, are mostly based on case reports, and there are few retrospective studies with large samples to explore their clinical features and treatment outcome. Therefore, investigators designed this retrospective clinical study to analyze the clinical characteristics, treatment, survival, and prognostic risk factors of patients with lymphoepithelioma-like carcinoma in order to summary the clinical character and guide treatment.

Condition Pulmonary Disease, Lung Neoplasm, Bronchial Neoplasm, Lung Cancer, Lung Disease, carcinoma lung, lung carcinoma, Lymphoepithelioma-Like Carcinoma, Lymphoepithelioma-Like Carcinoma of Thymus, Lymphoepithelioma-Like Carcinoma, Lymphoepithelioma-Like Carcinoma of Thymus
Treatment Non-intervention research
Clinical Study IdentifierNCT04614818
SponsorSun Yat-sen University
Last Modified on26 January 2021


Yes No Not Sure

Inclusion Criteria

Gender: Male or Female
Do you have any of these conditions: Lung Disease or Lymphoepithelioma-Like Carcinoma of Thymus or Pulmonary Disease or Lymphoepithelioma-Like Carcinoma or Lung Cancer or Lung Neoplasm or...?
Do you have any of these conditions: carcinoma lung or Bronchial Neoplasm or Lung Cancer or Pulmonary Disease or Lymphoepithelioma-Like Carcinoma of Thymus or Lung Disease or Lymphoepithe...?
\. Lymphoepithelioma-like carcinoma confirmed by histopathology
\. The primary lesion does not involve the nasopharynx
\. Complete data for patient's character, laboratory and imaging test, treatment and follow-up are available

Exclusion Criteria

\. Concomitant with other tumor components at the time of diagnosis
\. Have a history of any other malignant tumors
\. Lack of complete data
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note